Esoteric Testing Market by Type, Technology, End-user and Region
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Notice Regarding Recording of Extraordinary Loss (Business Restructuring Expenses) H.U. Group Holdings, Inc. (hereinafter, the Company ) hereby announces that it recorded an extraordinary loss in the consolidated results for fiscal year ended March 31, 2021, as described below. 1. Reason for recording extraordinary loss (business restructuring expenses) The business environment surrounding the H.U. Group is expected to continue to be difficult, especially in clinical testing market in Japan, reflecting the pressure to reduce laboratory test service costs associated with worsening business conditions of medical institutions and demand for healthcare expenditure reduction, as well as projected growth of healthcare expenditures caused mainly by aging of population and the introduction of advanced medicine. Moreover, appropriate response to recent changes in consumer behavior and patients self- restraint of seeking medical attention due to the spread
Notice Regarding Revision of Dividend Forecast (Commemorative Dividend) H.U. Group Holdings, Inc. (hereinafter, the Company ) hereby announces that it has revised its year-end dividend forecast for the fiscal year ended March 31, 2021, as stated in the Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (under Japanese GAAP) released today. Details are as follows. The subject matter will officially be determined by resolution of the Board of Directors at a meeting scheduled to be held on May 21, 2021. 1. Reason for revision of dividend forecast As stated in the Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (under Japanese GAAP) released today, the financial results for the fiscal year ended March 31, 2021 have been finalized and the Company decided to pay an ordinary dividend of 75 yen per share, which had previously been undecided. Moreover, in commemorating the 70th anniversary of its fou
Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+
from Treatment with Lynparza
More Than 20,000 Patients in Japan Now Qualify for Genetic Testing
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis
® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect.
vimarsana © 2020. All Rights Reserved.